NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 78 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2015. The put-call ratio across all filers is 97.39 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $30,000 | -18.9% | 71,015 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $37,000 | -28.8% | 71,015 | -21.4% | 0.00% | -50.0% |
Q1 2017 | $52,000 | -5.5% | 90,315 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $55,000 | -32.9% | 90,315 | 0.0% | 0.00% | -33.3% |
Q3 2016 | $82,000 | +115.8% | 90,315 | +27.2% | 0.01% | +100.0% |
Q2 2016 | $38,000 | -55.8% | 71,015 | -21.4% | 0.00% | -62.5% |
Q1 2016 | $86,000 | -9.5% | 90,315 | +27.2% | 0.01% | -33.3% |
Q4 2015 | $95,000 | -53.7% | 71,015 | -21.4% | 0.01% | -50.0% |
Q3 2015 | $205,000 | +88.1% | 90,315 | +32.8% | 0.02% | +84.6% |
Q2 2015 | $109,000 | 0.0% | 68,015 | 0.0% | 0.01% | 0.0% |
Q1 2015 | $109,000 | -14.8% | 68,015 | -0.1% | 0.01% | -23.5% |
Q4 2014 | $128,000 | +54.2% | 68,115 | +7.9% | 0.02% | +54.5% |
Q3 2014 | $83,000 | -6.7% | 63,115 | +5.0% | 0.01% | -15.4% |
Q2 2014 | $89,000 | -12.7% | 60,115 | 0.0% | 0.01% | -31.6% |
Q1 2014 | $102,000 | -18.4% | 60,115 | 0.0% | 0.02% | -13.6% |
Q4 2013 | $125,000 | -6.7% | 60,115 | +19.2% | 0.02% | -24.1% |
Q2 2013 | $134,000 | – | 50,420 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
Hudock, Inc. | 30,500 | $63,000 | 0.05% |
BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
BOLTON LP | 77,400 | $160,000 | 0.03% |